Turn selected targets into an mRNA message
An encoded target list still needs a controlled construct design before it can become a drug product. This is step six of the vaccine guide.
Before you start: mRNA construct anatomy separates the coding message from its supporting features. Antigen processing explains why encoding a sequence does not guarantee its display.
Where this step sits
Target selection defines what the response should recognize. Construct design defines the message cells will translate. Manufacturing then produces and tests the specified material.
The intuition: arrangement changes the message
Joining target segments into one long protein changes their neighbors. Linkers, ordering and trafficking features can change expression and processing. They may also produce unintended junctional fragments. A construct is therefore more than targets copied into a file.
Messenger ribonucleic acid (mRNA) supplies the instructions. A ribosome makes protein from them. Processing then generates potential peptides for human leukocyte antigen (HLA) display. These are three different objects: message, protein and displayed fragments.
Four design choices to inspect
| Choice | Purpose | Evidence needed |
|---|---|---|
| Coding windows and order | Include altered sequence and useful flanking context | Trace each window to the source event; assess new junctions |
| Linkers or spacers | Influence processing between segments | Product-relevant expression and presentation tests |
| Trafficking features | Direct protein toward a cellular compartment | Verify the route supports the intended display pathway |
| RNA features and chemistry | Support translation, stability and appropriate sensing | Measure expression, integrity and product-specific behavior |
A helper segment may support CD4 responses in a particular design. It is not universally required by every platform. Likewise, a linker that performed well in one model is not automatically best for all antigen windows or messenger-RNA products.
Keep the design and delivery records separate
An LNP (lipid nanoparticle) is one delivery formulation. RNA-lipoplex is a different architecture. The same coding message can behave differently in another formulation or route. A construct review cannot stand in for delivery or batch-release evidence.
A reviewable specification should preserve the complete sequence, the connection between each segment and its source, the intended protein product and the rationale for design choices. The released batch must be traceable to that version. A manufacturing adjustment can require renewed biological review.
Worked example: a linker revision
A fictional manufacturer proposes a shorter linker between two target windows. The target names remain unchanged. Reviewers still ask whether the encoded protein, processing predictions, unexpected junctions and measured presentation changed.
If the team accepts the edit, it records the approved revision and its supporting evidence. A verbal assurance that the same targets are included cannot establish comparability between the two constructs.
What can go wrong at this step
A sequence can lose an altered residue during handoff. A spacer may reduce intended processing or create a new candidate peptide. Strong expression may favor the wrong compartment. Quality tests may confirm a correctly manufactured message while leaving target display unresolved.
Try it
A new construct produces more protein in a cell assay. Has it shown better tumor recognition?
Answer: No. Expression is one result. The relevant fragments must be displayed and recognized; tumor recognition and safety need their own evidence.
Explain it back
“Construct design controls ___; delivery controls ___; release testing checks ___.” One answer: “the message and encoded product; how it reaches cells; the specified manufactured material.”
Takeaway
Trace the final message back to the selected targets and test changes at the biological step they could affect.
Next: Manufacture a defined product.
Sources and scope
Source check: October 8, 2026; expert and learner review pending. These questions do not specify a clinical construct.
- RNA-vaccine design principles — an infectious-disease review; cancer antigen choices require separate evidence.
- Primary RNA-lipoplex cancer-vaccine methods.
- Lipid delivery principles.